May Institute, an award-winning nonprofit organization that has over 60 years of experience with adults and children with autism spectrum disorder as well as other development disabilities, recently provided new resources for communicating with patients with autism.

The Tuberous Sclerosis Alliance (TS Alliance) recently announced that it has created the Engles Collaborative Research Fund, which will give $1.5 million to research for tuberous sclerosis complex (TSC) solutions.

A recent American Heart Association (AHA) 'Scientific Statement' reports that many children in the U.S. do not have ideal childhood cardiovascular health, according to the standards defined by the AHA.

Takeda Pharmaceutical Company Limited and Ultragenyx Pharmaceutical Inc., a company that develops products for rare and ultra-rare diseases, recently announced a strategic partnership for developing and commercializing therapies.

The nation is in a watershed moment that will decide the future of health care in the U.S. following Aetna's  announcement earlier this week that it will dramatically scale back its participation in the Affordable Care Act, U.S. Rep. Renee Ellmers (R-N.C.) said during a recent interview. 

Aetna’s announcement that it will reduce its Affordable Care Act (ACA) participation to four state exchanges in 2017 is the latest bad news for consumers who buy their health insurance through the ACA marketplace and another cause for criticism for the president's signature legislation. 

Mary Grealy, president of the Healthcare Leadership Council, recently released a statement about the passing of Mike Bromberg, who was a health care policy leader in the U.S.

Leaders with the Multiple Sclerosis Association of America (MSAA) recently announced that it has launched a new online support community for people with multiple sclerosis (MS).

Amgen and Advaxis Inc. recently announced that they have entered a worldwide partnership to develop and sell ADXS-NEO, a preclinical investigational cancer immunotherapy treatment.

The American Health Council recently announced that it has chosen Virginia Lipke, an international infection control practitioner at the Centers for Disease Control and Prevention (CDC), as its new nursing board member.

The National Institute of Allergy and Infectious Disease (NIAID) recently reported that people with Ebola virus infections are 20 percent more likely to overcome the infection and survive if they also had co-infections of Plasmodium parasites, which cause malaria.

A fundamental misunderstanding of competitive markets has lead to health care insurance providers pulling out of the Obamacare exchanges, leaving consumers in a bind and contributing to the dismal state of the Affordable Care Act (ACA), according to a Republican North Carolina congressional representative.

Dara Torres, an Olympic athlete, recently partnered with Celgene to increase awareness of psoriasis through the company’s Show More of You campaign in the U.S.

Eli Lilly and Company recently announced that it has promoted Joshua Smiley to senior vice president and Anat Ashkenazi to vice president of finance and treasurer as Thomas Grein retires.

The Epilepsy Foundation Sudden Unexpected Death in Epilepsy (SUDEP) Institute recently announced the winners of the organization’s third challenge to identify biomarkers that could predict SUDEP in epilepsy patients.

The National Institutes of Health (NIH) recently distributed $9.4 million in grants to the City University of New York, the Albert Einstein College of Medicine and Montefiore to conduct HIV research in central Africa.

Aurinia Pharmaceutical Company recently announced that the phase IIB clinical study of its voclosporin therapy for active lupus nephritis, or lupus-related kidney disease, has been successful.

The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the National Institutes of Health (NIH), recently found that approximately 80 percent of preschool children with peanut allergies had positive responses to oral immunotherapy.

Leaders from ViiV Healthcare have launched a phase III program to find more supportive evidence for its dolutegravir (Tivicay) and lamivudine (Epivir) treatments, which are designed for adults with HIV-1 infections.

Leaders with the Epilepsy Foundation recently partnered with the American Epilepsy Society (AES) to award grants to two medical research, funding their work in researching and research training for epilepsy.